Ron van Schaik

1.4k total citations
29 papers, 553 citations indexed

About

Ron van Schaik is a scholar working on Pharmacology, Oncology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Ron van Schaik has authored 29 papers receiving a total of 553 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pharmacology, 7 papers in Oncology and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Ron van Schaik's work include Pharmacogenetics and Drug Metabolism (10 papers), Pharmacological Effects and Toxicity Studies (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Ron van Schaik is often cited by papers focused on Pharmacogenetics and Drug Metabolism (10 papers), Pharmacological Effects and Toxicity Studies (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Ron van Schaik collaborates with scholars based in Netherlands, Italy and United States. Ron van Schaik's co-authors include Jan Lindemans, Marchina van der Ende, Herman G. Sprenger, Frank P. Kroon, David M. Burger, Charles la Porte, Clemens Richter, Paul W. Schenk, Peter J. Koopmans and P. H. P. Groeneveld and has published in prestigious journals such as Blood, Cancer Research and European Heart Journal.

In The Last Decade

Ron van Schaik

26 papers receiving 539 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ron van Schaik Netherlands	9	173	147	113	104	103	29	553
P. Neuhaus Germany	8	131 0.8×	288 2.0×	202 1.8×	126 1.2×	85 0.8×	11	652
Rubin Lubomirov Spain	13	374 2.2×	162 1.1×	132 1.2×	98 0.9×	128 1.2×	38	717
Elizabeth Formentini United States	10	176 1.0×	178 1.2×	99 0.9×	44 0.4×	82 0.8×	15	555
Marelize Swart South Africa	14	244 1.4×	232 1.6×	106 0.9×	117 1.1×	96 0.9×	26	607
Marie‐Claude Gagnieu France	19	278 1.6×	64 0.4×	145 1.3×	169 1.6×	102 1.0×	63	889
Thao Doan United States	13	126 0.7×	31 0.2×	65 0.6×	80 0.8×	71 0.7×	35	543
Heike Tegude Germany	8	185 1.1×	328 2.2×	360 3.2×	113 1.1×	176 1.7×	9	704
Sylvie Quaranta France	11	83 0.5×	123 0.8×	181 1.6×	153 1.5×	100 1.0×	27	403
Holli H. Dilks United States	10	153 0.9×	204 1.4×	44 0.4×	110 1.1×	102 1.0×	17	654
Kersti Oselin Estonia	15	114 0.7×	71 0.5×	373 3.3×	70 0.7×	237 2.3×	41	721

Countries citing papers authored by Ron van Schaik

Since Specialization

Citations

This map shows the geographic impact of Ron van Schaik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ron van Schaik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ron van Schaik more than expected).

Fields of papers citing papers by Ron van Schaik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ron van Schaik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ron van Schaik. The network helps show where Ron van Schaik may publish in the future.

Co-authorship network of co-authors of Ron van Schaik

This figure shows the co-authorship network connecting the top 25 collaborators of Ron van Schaik. A scholar is included among the top collaborators of Ron van Schaik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ron van Schaik. Ron van Schaik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lingsma, Hester F., et al.. (2025). Interaction of CYP2C19 with the effect of clopidogrel in secondary prevention of major ischemic events: Systematic review and meta-analysis. International Journal of Stroke. 21(3). 324–334.

Yin, Dean R.P.P. Chan Pin, et al.. (2024). Real-world implementation of a genotype-guided p2y12-inhibitor de-escalation strategy in acute coronary syndrome patients. European Heart Journal. 45(Supplement_1). 1 indexed citations

Crucitta, Stefania, Federico Cucchiara, Ron H.J. Mathijssen, et al.. (2022). Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. Cancer Treatment Reviews. 104. 102340–102340. 53 indexed citations

Willemsen, Sten P., Melek Rousian, Mina Mirzaian, et al.. (2022). Periconceptional Maternal Protein Intake from Animal and Plant Sources and the Impact on Early and Late Prenatal Growth and Birthweight: The Rotterdam Periconceptional Cohort. Nutrients. 14(24). 5309–5309. 4 indexed citations

Visser, Sabine, Stijn L.W. Koolen, Nico van Walree, et al.. (2021). Genetic polymorphism in ATIC is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer. Thorax. 76(11). 1150–1153. 6 indexed citations

Mian, Paola, et al.. (2019). High Levels of Several Antipsychotics and Antidepressants due to a Pharmacogenetic Cause: A Case Report. Pharmacogenomics. 20(8). 567–570. 3 indexed citations

Re, Marzia Del, Stefania Crucitta, Andrea Sbrana, et al.. (2019). Androgen receptor (AR) splice variant 7 and full‐length AR expression is associated with clinical outcome: a translational study in patients with castrate‐resistant prostate cancer. British Journal of Urology. 124(4). 693–700. 30 indexed citations

Černe, Darko, Irene Mancini, Lisa Simi, et al.. (2018). Personalized laboratory medicine: a patient-centered future approach. Clinical Chemistry and Laboratory Medicine (CCLM). 56(12). 1981–1991. 29 indexed citations

Kabakchiev, Boyko, et al.. (2018). User considerations in assessing pharmacogenomic tests and their clinical support tools. npj Genomic Medicine. 3(1). 26–26. 40 indexed citations

10.

Lloberas, Núria, Laure Elens, Inés Llaudó, et al.. (2017). The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation. Pharmacogenetics and Genomics. 27(9). 313–322. 56 indexed citations

11.

Pazzagli, Mario, Francesca Malentacchi, Irene Mancini, et al.. (2015). Personalized laboratory medicine: Results of an european survey conducted by the EFLM/ESPT WG-PLM. Clinical Chemistry and Laboratory Medicine (CCLM). 53.

12.

Mancini, Irene, Pamela Pinzani, Lisa Simi, et al.. (2014). Implementation of a companion diagnostic in the clinical laboratory: The BRAF example in melanoma. Clinica Chimica Acta. 439. 128–136. 6 indexed citations

13.

Rousseau, François, David Gancberg, Heinz Schimmel, et al.. (2009). Considerations for the development of a reference method for sequencing of haploid DNA – an opinion paper on behalf of the IFCC Committee on Molecular Diagnostics. International Federation of Clinical Chemistry and Laboratory Medicine. Clinical Chemistry and Laboratory Medicine (CCLM). 47(11). 1343–50. 6 indexed citations

14.

Deenik, Wendy, Bronno van der Holt, Jeroen J. W. M. Janssen, et al.. (2009). Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1) Predict for Molecular Resistance in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) Receiving High-Dose Imatinib.. Blood. 114(22). 2208–2208. 2 indexed citations

15.

Straaten, Tahar van der & Ron van Schaik. (2009). Genetic Techniques for Pharmacogenetic Analyses. Current Pharmaceutical Design. 16(2). 231–237. 5 indexed citations

16.

Gelder, Teun van, Ferdi Sombogaard, Ron van Schaik, et al.. (2008). IMPDH ACTIVITY IS CORRELATED WITH THE 3757T>C POLYMORPHISM IN THE IMPDH TYPE 2 GENE IN MMF TREATED KIDNEY TRANSPLANT PATIENTS. Transplantation. 86(2S). 37–37. 1 indexed citations

17.

Burger, David M., Charles la Porte, Marchina van der Ende, et al.. (2005). Interpatient variability in the pharmacokinetics of the HIV non‐nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. British Journal of Clinical Pharmacology. 61(2). 148–154. 180 indexed citations

18.

Visser, Loes E., Ron van Schaik, M. van Vliet, et al.. (2004). The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thrombosis and Haemostasis. 92(7). 61–66. 72 indexed citations

19.

Gelder, Teun van, Dennis A. Hesselink, Reinier M. van Hest, Ron A. A. Mathôt, & Ron van Schaik. (2004). Pharmacogenetics in Immunosuppressive Therapy. Therapeutic Drug Monitoring. 26(4). 343–346. 14 indexed citations

20.

Heiden, Ilse P. van der, Erik A.C. Wiemer, Rob Pieters, et al.. (2003). MDR‐1 C3435T gene polymorphism does not correlate with P‐Glycoprotein expression and function in acute myeloid leukemia. Clinical Pharmacology & Therapeutics. 73(2). 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact